Esperion Therapeutics (ESPR) Aktienübersicht
Esperion Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das Medikamente zur Behandlung von Patienten mit erhöhtem Low-Density-Lipoprotein-Cholesterin (LDL-C) in den Vereinigten Staaten entwickelt und vermarktet. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 5/6 |
| Künftiges Wachstum | 5/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 1/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
ESPR Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Esperion Therapeutics, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$3.19 |
| 52-Wochen-Hoch | US$4.18 |
| 52-Wochen-Tief | US$1.10 |
| Beta | 1.06 |
| 1 Monat Veränderung | 1.59% |
| 3 Monate Veränderung | 47.00% |
| 1 Jahr Veränderung | 157.26% |
| 3 Jahre Veränderung | 111.26% |
| 5 Jahre Veränderung | -81.96% |
| Veränderung seit IPO | -78.00% |
Aktuelle Nachrichten und Updates
Narrativ-Update • Jun 22
ESPR: Downgrades And Pending ArchiMed Deal Will Shape Balanced Forward Outlook
Esperion Therapeutics' updated analyst price target has shifted from about $6.50 to roughly $3.20, as analysts point to revised assumptions for revenue growth, profit margins, and future P/E multiples following a recent wave of downgrades. Analyst Commentary Recent Street research on Esperion Therapeutics clusters around a series of downgrades, with analysts reassessing how the company executes on its growth plans and what that could mean for valuation.
Narrativ-Update • Jun 04
ESPR: Vision 2040 Execution And Corstasis Integration Will Offset Recent Downgrades
Esperion Therapeutics' updated analyst price target holds at $3.16 per share, as analysts weigh a higher discount rate and softer revenue growth assumptions against slightly better profit margin expectations and a modestly lower future P/E, all set against recent downgrades and an earlier move by Citizens to raise its target to $5 from $4 on continued execution of the Vision 2040 plan. Analyst Commentary Recent Street research on Esperion has shifted in a clearly more cautious direction, with several bearish analysts moving to less constructive ratings even as the average price target holds near US$3.16 per share.Recent updates
Narrativ-Update • Jun 22
ESPR: Downgrades And Pending ArchiMed Deal Will Shape Balanced Forward Outlook
Esperion Therapeutics' updated analyst price target has shifted from about $6.50 to roughly $3.20, as analysts point to revised assumptions for revenue growth, profit margins, and future P/E multiples following a recent wave of downgrades. Analyst Commentary Recent Street research on Esperion Therapeutics clusters around a series of downgrades, with analysts reassessing how the company executes on its growth plans and what that could mean for valuation.Narrativ-Update • Jun 04
ESPR: Vision 2040 Execution And Corstasis Integration Will Offset Recent Downgrades
Esperion Therapeutics' updated analyst price target holds at $3.16 per share, as analysts weigh a higher discount rate and softer revenue growth assumptions against slightly better profit margin expectations and a modestly lower future P/E, all set against recent downgrades and an earlier move by Citizens to raise its target to $5 from $4 on continued execution of the Vision 2040 plan. Analyst Commentary Recent Street research on Esperion has shifted in a clearly more cautious direction, with several bearish analysts moving to less constructive ratings even as the average price target holds near US$3.16 per share.
Narrativ-Update • May 19
ESPR: Vision 2040 Plans And Acquisition Are Weighed Against Downgrade Risks
Esperion Therapeutics' updated analyst price target has moved from about $15.92 to $3.28 as analysts factor in a series of recent downgrades alongside mixed sentiment around execution on longer term plans and pipeline expansion. Analyst Commentary Recent research has been dominated by downgrades, but there are still a few points that bullish analysts highlight when they look at Esperion Therapeutics and its current valuation.Narrativ-Update • May 04
ESPR: Vision 2040 And Corstasis Deal Will Balance Downgrade Concerns
Narrative Update on Esperion Therapeutics The updated analyst price target for Esperion Therapeutics has moved closer to recent Street views, rising from a fair value estimate of $1.78 to $3.16. Analysts are weighing recent downgrades against research that cites consistent Q4 results, progress on the Vision 2040 plan, and pipeline expansion, including the Corstasis Therapeutics acquisition and ESP-2001 advancement.Narrativ-Update • Apr 20
ESPR: Vision 2040 Progress Will Likely Mask Corstasis Execution Risk
Analysts recently lifted their price target on Esperion Therapeutics to $5 from $4, citing Q4 results that aligned with earlier guidance and continued progress on the Vision 2040 plan, including the Corstasis Therapeutics acquisition and advancement of ESP-2001. Analyst Commentary Recent commentary around Esperion focuses on how the updated US$5 price target lines up with the company’s execution on its Vision 2040 plan.Narrativ-Update • Apr 06
ESPR: Vision 2040 And Corstasis Deal Will Likely Expose Execution Risks
Analysts raised their price target on Esperion Therapeutics to $5 from $4, citing the company's Q4 results, continued execution of its Vision 2040 plans, the acquisition of Corstasis Therapeutics, and progress with ESP-2001 as key reasons for the update. Analyst Commentary The latest research update highlights that the higher US$5 price target reflects Q4 results that were in line with January guidance, along with continued execution of the Vision 2040 plans.Narrativ-Update • Mar 23
ESPR: Vision 2040 Execution And ESP-2001 Progress Will Drive Future Upside
Narrative Update Overview Analysts have lifted their price target on Esperion Therapeutics to $5, up from $4, citing continued execution on Vision 2040, the Corstasis Therapeutics acquisition, and progress with ESP-2001 as key drivers behind the updated valuation inputs. These inputs include a higher fair value estimate and adjusted discount rate and P/E assumptions.Narrativ-Update • Mar 09
ESPR: Patent Litigation Outcomes Will Likely Expose Weak Profitability Execution Risks
Analysts have revised their price target for Esperion Therapeutics to align with updated assumptions that keep fair value steady at about $1.78 per share. This reflects higher modeled revenue growth, balanced by lower projected profit margins and a slightly reduced future P/E multiple.Narrativ-Update • Feb 22
ESPR: Overweight Rating Will Likely Conceal Risk Around Patent And Profitability Execution
Analysts have adjusted their price target on Esperion Therapeutics to $9, reflecting updated assumptions for revenue growth, profit margin, and forward P/E. This change is supported by recent Street research highlighting the new coverage and target level.Narrativ-Update • Feb 08
ESPR: Overweight Rating Will Likely Mask Execution Risk Around Acquisition Strategy
Analysts have raised their price target for Esperion Therapeutics to about US$1.78 from roughly US$1.72, citing updated assumptions around revenue growth, profit margins, discount rate, and future P/E. These changes reflect the recent US$9 initiation from Piper Sandler as part of a broader reassessment of the stock's earnings power and risk profile.Narrativ-Update • Jan 24
ESPR: Overweight Rating And Accretive Deal Hunt Will Support Bullish Sentiment
Analysts have nudged their price target for Esperion Therapeutics slightly higher to around US$6.50, citing updated assumptions for revenue growth, profit margin and future P/E that are generally consistent with recent Street research, including the new US$9 target from Piper Sandler. Analyst Commentary Analysts are using the new US$9 reference point to frame both the upside case and the key execution questions around Esperion Therapeutics, with the latest work focusing on how current assumptions for revenue, profit margin and future P/E might play out over time.Narrativ-Update • Jan 07
ESPR: Overweight Rating Will Likely Obscure Persistent Execution And Profitability Risks
Narrative Update on Esperion Therapeutics Analysts have lifted their price target on Esperion Therapeutics to US$9, citing updated assumptions for revenue growth, profitability, and future P/E that reflect a more constructive view of the company’s earnings potential. Analyst Commentary Recent coverage highlights a more constructive stance on Esperion Therapeutics, with a US$9 price target used as a reference point for what the business might be worth if current assumptions on revenue and earnings play out as expected.Narrativ-Update • Dec 23
ESPR: Rising Street Optimism Will Likely Mask Lingering Execution Risks
Analysts have raised their price target on Esperion Therapeutics to $9.00 from $7.00, reflecting increased confidence in the stock's valuation despite moderating long term growth and margin assumptions. Analyst Commentary Recent Street research has reflected a cautiously optimistic stance toward Esperion Therapeutics, with new coverage and revised price targets coalescing around the $9 level.Narrativ-Update • Dec 09
ESPR: Rising Overweight Ratings Will Support Bullish Sentiment Toward Shares
Analysts have nudged their price target for Esperion Therapeutics higher to approximately $6.50 per share from about $6.15, citing supportive Street research, including recent Overweight initiations and target increases. These changes reflect confidence in the company’s longer term earnings multiple despite slightly tempered growth and margin assumptions.Narrativ-Update • Nov 25
ESPR: Overweight Ratings And Positive Developments Will Strengthen Bullish Outlook For Shares
Analysts have raised their price target for Esperion Therapeutics from $7 to $9 per share. This reflects improved expectations for the company's revenue growth and fair value based on recent positive coverage and outlook updates.Narrativ-Update • Nov 09
ESPR: Price Target Increase Will Drive Renewed Confidence In Future Performance
Analysts have raised their price target for Esperion Therapeutics from $7 to $9, citing improved growth and profitability expectations. Analyst Commentary Bullish Takeaways Bullish analysts have increased their price targets, reflecting growing confidence in the company's outlook and execution capabilities.Seeking Alpha • Sep 09
Esperion: A Mixture Of Opportunity And Risk: Why I Would Hold For Now
Summary Esperion's stock surged over 30% this month after Q2 results beat expectations, driven by strong U.S. sales and global partnerships. The company benefits from high-margin collaboration revenues and expanding international milestones but faces heavy debt and declining cash reserves. Patent settlements protect U.S. exclusivity through 2040, yet ongoing litigation and financial strain add significant risk to the investment thesis. Given the mix of opportunity and risk, I assign a Hold rating until Esperion demonstrates consistent profitability and improved financial stability. Read the full article on Seeking AlphaNarrativ-Update • Aug 06
Rising Digital Adoption And Global Partnerships Will Shape Future Markets
Esperion Therapeutics' consensus price target has increased as analysts now assign a higher future P/E despite a decline in net profit margin, resulting in the APT rising from $5.79 to $6.50. What's in the News Esperion Therapeutics was dropped from the S&P Pharmaceuticals Select Industry Index.
Neues Narrativ • May 04
US FDA Approvals And Global Expansion Will Shape Future Markets
International expansion and strategic partnerships are anticipated to significantly boost global sales and royalty revenues over time.Seeking Alpha • Feb 22
Esperion Therapeutics: Little Upside Potential In Their Earlier Generation Drug
Summary Esperion Therapeutics has two approved LDL-C lowering therapies, Nexletol and Nexlizet, but lacks a strong pipeline for future growth. Recent label expansions for Nexletol and Nexlizet have broadened their indications, but competition from Merck's PCSK9 inhibitor could impact ESPR's market position. Financially, Esperion has limited cash runway and faces challenges from more effective and safer LDL-C lowering treatments like PCSK9 inhibitors. Despite trading near 52-week lows, I see little upside in investing in Esperion due to its moderate benefits and lack of a robust pipeline. Read the full article on Seeking AlphaSeeking Alpha • Dec 08
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Summary Esperion Therapeutics' stock broke out above a year-long trading range, signaling a potential sustainable breakout if support at $3.40 holds. Despite past skepticism and price fades, recent technical achievements and strategic moves, including global drug submissions, bolster the stock's outlook. The Piper Sandler Conference reinforced Esperion's growth strategy, with CEO Sheldon Koenigand CFO Ben Halladay providing encouraging news on guidance and business performance. Insider ownership remains low, which could impact confidence, but the company's strategic positioning and milestones present a compelling investment case. Read the full article on Seeking AlphaSeeking Alpha • Nov 13
Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
Summary I maintain my buy rating on Esperion Therapeutics due to its strong Q3 2024 financial performance, showcasing consistent revenue growth and market adoption. The Company's aggressive commercialization efforts, including market coverage expansion and sales force growth, have significantly boosted retail prescriptions and broadened future revenue streams. International expansion through partnerships with Daiichi Sankyo Europe and Otsuka Pharmaceutical has driven prescription and revenue growth, strengthening ESPR's global presence. Technical analysis indicates bullish momentum with no signs of reversal, supported by positive financials and key growth drivers, making ESPR a buy. Read the full article on Seeking AlphaSeeking Alpha • Aug 16
Esperion Therapeutics: Strategically Positioned To Grow
Summary Esperion is a pharmaceutical firm whose focus is to treat patients with high low-density lipoprotein cholesterol (LDL-C). I rate it a buy due to strategic initiatives and market potential driving significant growth. Strong revenue growth and margin expansions reflect improving financial performance and market breakthrough. ESPR's unique non-statin medicines address unmet demand, offering a competitive advantage in the large and growing LDL-C-lowering pharmaceutical market. Read the full article on Seeking AlphaSeeking Alpha • May 20
Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
Summary Esperion Therapeutics secured FDA approval for expanded labels of its flagship drugs and obtained a patent extension. Despite these successes, the stock trades with the weight of an abiding skepticism. The company's Q1 showed accelerating revenue growth, but guidance offered little new information. A lipid lurker marketing campaign shows early top of the funnel success, but there is little data yet to demonstrate bottom funnel performance. Still, with the stock trading at a valuation discount, I continue to buy ESPR in expectation of significant upside once the company shows evidence of exponential growth and healthy profitability. Read the full article on Seeking AlphaSeeking Alpha • Feb 28
A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Summary Esperion Therapeutics reported strong Q4 and full-year revenue growth, with total revenue increasing 72% YoY to $32.3M in Q4 and 54% YoY to $116M for the full year. The company expects a true inflection point after receiving approval for expanded labels for its cardiovascular drugs. Esperion is preparing for a significant sales ramp starting in April, with an expanded sales force and an anticipated larger patient population. Read the full article on Seeking AlphaSeeking Alpha • Jan 22
Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Summary Esperion Therapeutics' stock gapped down after news of a stock offering but fortunately never reached the $1.50 offering price. The presentation at the JP Morgan Healthcare Conference provided little new information and failed to boost the stock. The Q&A session provided some insights, including information about utilization management headwinds and the company's digital consumer campaign. Altogether, the company appears to be stuck in a "prove it" box and needs to demonstrate a compelling path to profitability to maintain interest in investing in the promise of its drugs. Read the full article on Seeking AlphaSeeking Alpha • Jan 14
Esperion Is Sitting On A Potential Blockbuster Drug
Summary Esperion Therapeutics has a potential blockbuster drug that is gaining traction among the medical community. The company's main drugs, NEXLIZET and NEXLETOL, have been approved by the FDA and offer alternatives to statins for lowering LDL cholesterol. Recent developments, including an expanded labeling and influential endorsements from doctors like Peter Attia, suggest potential growth for the company. Read the full article on Seeking AlphaAnalyseartikel • Jun 19
Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Esperion Therapeutics, Inc.'s ( NASDAQ:ESPR ) price-to-sales (or "P/S") ratio of 1.7x might make it look like a buy...Aktionärsrenditen
| ESPR | US Pharmaceuticals | US Markt | |
|---|---|---|---|
| 7D | 0.9% | -0.5% | 0.6% |
| 1Y | 157.3% | 45.8% | 19.5% |
Rendite im Vergleich zur Industrie: ESPR übertraf die Branche US Pharmaceuticals , die im vergangenen Jahr eine Rendite von 45.8 erzielte.
Rendite vs. Markt: ESPR übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.5 erzielte.
Preisvolatilität
| ESPR volatility | |
|---|---|
| ESPR Average Weekly Movement | 16.3% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.2% |
Stabiler Aktienkurs: Der Aktienkurs von ESPR war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: ESPRDie wöchentliche Volatilität (16%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2008 | 294 | Sheldon Koenig | www.esperion.com |
Esperion Therapeutics, Inc. ist ein biopharmazeutisches Unternehmen, das in den Vereinigten Staaten Medikamente zur Behandlung von Patienten mit erhöhtem Low-Density-Lipoprotein-Cholesterin (LDL-C) entwickelt und vermarktet. Zu den vermarkteten Produkten des Unternehmens gehören NEXLETOL (Bempedoinsäure) und NEXLIZET (Bempedoinsäure und Ezetimib), Tabletten, die einmal täglich oral eingenommen werden und nicht zur Behandlung der primären Hyperlipidämie bei Erwachsenen mit heterozygoter familiärer Hypercholesterinämie und Herz-Kreislauf-Erkrankungen dienen, die eine zusätzliche Senkung des LDL-C erfordern. Zu den Produkten des Unternehmens gehören auch NILEMDO, ein ATP-Citrat-Lyase (ACL)-Inhibitor, der den LDL-C-Wert und das kardiovaskuläre Risiko durch Verringerung der Cholesterinbiosynthese und Hochregulierung der LDL-Rezeptoren senkt, sowie NUSTENDI, eine Tablette mit Bempedosäure und Ezetimib zur Behandlung von erhöhtem LDL-C-Wert.
Esperion Therapeutics, Inc.'s Grundlagenzusammenfassung
| ESPR grundlegende Statistiken | |
|---|---|
| Marktanteil | US$822.04m |
| Gewinn(TTM) | -US$7.42m |
| Umsatz(TTM) | US$418.24m |
2.0x
Kurs-Umsatz-Verhältnis-110.7x
Kurs-Gewinn-Verhältnis Ist ESPR zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ESPR Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$418.24m |
| Kosten der Einnahmen | US$176.54m |
| Bruttogewinn | US$241.70m |
| Sonstige Ausgaben | US$249.13m |
| Gewinn | -US$7.42m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.029 |
| Bruttomarge | 57.79% |
| Nettogewinnspanne | -1.77% |
| Schulden/Eigenkapital-Verhältnis | -175.8% |
Wie hat sich ESPR auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/09 15:15 |
| Aktienkurs zum Tagesende | 2026/07/09 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Esperion Therapeutics, Inc. wird von 16 Analysten beobachtet. 6 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Jason Zemansky | BofA Global Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Jason Butler | Citizens JMP Securities, LLC |